Navigation Links
ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
Date:2/11/2013

SAN DIEGO, Feb. 11, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has initiated dosing in a thorough QT/QTc study (TQT study) of ANX-188.  

Brian M. Culley , Chief Executive Officer, said: "Consistent with our guidance from October 2011 and our commitment to FDA, we have initiated this study before the end of the first quarter.  We were pleased with the discussion we had with the Agency on the study protocol and our agreement on the supra-therapeutic dose." 

Santosh Vetticaden, Chief Medical Officer, said: "The FDA requires an assessment of cardiac repolarization for most new drugs having systemic bioavailability. This study will assess whether or not ANX-188 has an effect on QT prolongation. The study should complete dosing in the first quarter, and we expect to announce results in the second quarter of 2013."

The objective of the TQT study is to evaluate the effect of therapeutic and supra-therapeutic doses of ANX-188 on cardiac ventricular repolarization, specifically the QT-interval, in healthy volunteers.  The study is a single center, four-period, four-way cross-over, placebo- and positive-controlled, double-blind, randomized trial.  Sixty subjects will be enrolled.  Each subject will receive each of four treatments (placebo, active control, ANX-188 therapeutic dose, ANX-188 supra-therapeutic dose) during each of the four treatment periods.  

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions.  The C
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Announces Establishment of Regulatory Advisory Board
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
4. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
5. Applied Genetics Initiates Commercial Operation
6. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
9. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
10. Positive Clinical Study Results for BSPs HyperQ Technology
11. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 AcelRx Pharmaceuticals, Inc. ... company focused on the development and commercialization of ... breakthrough pain, today announced that it will release ... market close on Monday, March 9th, 2015. AcelRx ... 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) ...
(Date:3/4/2015)... Vegalab announced the acquisition of Ecowin, a ... As part of the acquisition, Ecowin rebranded itself as ... role as CEO for the company,s Korea operations. ... alongside Koo and oversee developments at the new location. ... Koo founded Ecowin in 2008 to great ...
(Date:3/4/2015)... 4, 2015 Launched by ... in December 2011, ,SARAH, - the ... microspheres versus sorafenib in advanced hepatocellular carcinoma (HCC) has ...   SARAH, a large French study of ... or HCC) has completed patient enrolment, exceeding its 400-patient ...
(Date:3/4/2015)... , March 4, 2015 ... Entwicklungen für Diagnostik und Therapie, Strahlendosismanagement und IT-Lösungen ... Royal Philips (NYSE: PHG, AEX: ... Röntgenkongress 2015 (ECR) bekannt, der vom 4. bis ... An den Ständen Nr. 102 and 110 ...
Breaking Biology Technology:AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6
... the job search engine dedicated to recruiting exceptional talent ... are some of the most rewarding careers on the ... The StartUpHire website, www.startuphire.com , lists ... geography, functional area, investor, and more. Search agents ...
... Israel, March 18 XTL Biopharmaceuticals Ltd. (Nasdaq: ... its Extraordinary General Meetings ("EGMs") held earlier today.All of ... board of directors consists of Mark Allouche, Dafna Cohen, ... Amit Yonay was also appointed Chairman. Dafna Cohen ...
... low-dose cohorts plus data from subsequent higher-dose cohorts to ... InterMune, Inc. (Nasdaq: ITMN ) today announced ... (R7227) in combination with polymerase inhibitor R7128 (Roche/Pharmasset), referred ... oral presentation in the late-breaker session at the 44th ...
Cached Biology Technology:StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies 2StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies 3Extraordinary General Meetings Statement -- XTL Also Announces Board and Management Changes 2INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 2INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 3INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 4
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of the "Global Biometrics ... their offering. The market for biometric ... CAGR of around 14% till 2020 ... will be increasing security needs, government projects and ...
(Date:3/3/2015)... 3, 2015 Cryoport, Inc. (OTCBB: ... cryogenic logistics solutions for the life sciences ... cell lines, clinical research organizations, vaccine manufacturers, ... the expansion of its relationship with ... Hutch") Clinical Research Division with the inclusion ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... Calif., Jan. 12, 2011 The agreement grants ... services, and secures supply of Codexis enzymes for ... by DSM,s InnoSyn™ route scouting services. ... processes for active pharmaceutical ingredients and intermediates which ...
... Immediate Release January 12, 2011 (Toronto) Seven ... (CAMH) have been awarded Young Investigator grant awards by ... The CAMH awards will fund genetic, clinical and ... personalized approaches for people with schizophrenia and depression. ...
... Pentagon build reliable mind-controlled prosthetic devices that military and ... Prosthetic limbs that can be maneuvered by ... there are challenges to making them work in the ... implants, nearly inevitable failure over time, often in a ...
Cached Biology News:DSM and Codexis Sign Enzyme Supply Agreement 2DSM and Codexis Sign Enzyme Supply Agreement 3DSM and Codexis Sign Enzyme Supply Agreement 47 CAMH scientists win Young Investigator awards focused on breakthrough research 27 CAMH scientists win Young Investigator awards focused on breakthrough research 3University of Houston researchers helping Pentagon build mind-controlled prosthetics 2University of Houston researchers helping Pentagon build mind-controlled prosthetics 3
... Polymerase is the most thoroughly characterized enzyme ... to its overall utility and efficacy. , ... for PCR applications. , It is ... ,, AmpliTaq DNA Polymerase is a 94 ...
... GCpro Taq DNA Polymerase is a versatile ... for all PCR applications. GCpro Taq DNA ... expressed in E. coli, containing the DNA ... enzyme includes a highly processive 5'-3' DNA ...
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
APO(a) EIA Sample Size: 25 l...
Biology Products: